Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Esophageal Cancer Clinical Trials

106 recruiting trials for Esophageal Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
106
Total Trials
106
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06293898

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Sponsor: SystImmune Inc.Enrolling: 28017 locations
RECRUITINGNCT07124000

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior...

Sponsor: AstraZenecaEnrolling: 10017 locations
RECRUITINGPhase 1NCT04999761

AB122 Platform Study

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each...

Sponsor: Taiho Pharmaceutical Co., Ltd.Enrolling: 9179 locations
RECRUITINGNCT06926374

Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery

Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system...

Sponsor: Chinese University of Hong KongEnrolling: 901 location
RECRUITINGPhase 1NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With...

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in...

Sponsor: Genentech, Inc.Enrolling: 45020 locations
RECRUITINGPhase 1NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck,...

Sponsor: PfizerEnrolling: 31020 locations
RECRUITINGNCT06605404

Pan-tumor MRD Study

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage...

Sponsor: Paradigm HealthEnrolling: 13502 locations
RECRUITINGPhase 1 / Phase 2NCT06006390

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to...

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 603 locations
RECRUITINGPhase 2NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of...

Sponsor: Daiichi SankyoEnrolling: 74020 locations
RECRUITINGPhase 1NCT06910657

IDOV-Immune for Advanced Solid Tumors

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not...

Sponsor: ViroMissile, Inc.Enrolling: 786 locations
RECRUITINGNCT06116019

Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)

The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian/SHS ETHOS treatment system. In this study, radiation treatment...

Sponsor: Charite University, Berlin, GermanyEnrolling: 6491 location
RECRUITINGPhase 1 / Phase 2NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 2856 locations
RECRUITINGPhase 1NCT06673329

Brodalumab in the Treatment of Immune-Related Adverse Events

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects...

Sponsor: Brian Henick, MDEnrolling: 111 location
RECRUITINGNCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal...

Sponsor: University of NebraskaEnrolling: 99999920 locations
RECRUITINGPhase 2 / Phase 3NCT07000253

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric...

Purpose of the Study: This clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better...

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Enrolling: 2902 locations
RECRUITINGPhase 2NCT06008054

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or...

This phase II study is a clinical study to explore the efficacy and safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 3761 location
RECRUITINGPhase 2NCT06535607

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic...

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

Sponsor: AstraZenecaEnrolling: 25720 locations
RECRUITINGNCT02198976

Australian Barrett's Cohort With Dysplasia and Early Cancer Study

The purpose of this study is to collect prospective observational data regarding endoscopic management and outcomes of patients with Barrett's oesophagus (BO) with high grade...

Sponsor: Professor Michael BourkeEnrolling: 3001 location
RECRUITINGNCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international...

Sponsor: Sanford HealthEnrolling: 200002 locations
RECRUITINGNCT07266363

Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma (ESCC) remains a highly lethal cancer worldwide, largely due to late diagnosis. Current screening methods such as upper endoscopy are invasive,...

Sponsor: City of Hope Medical CenterEnrolling: 6001 location
RECRUITINGPhase 2 / Phase 3NCT07221149

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in...

The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants...

Sponsor: Bristol-Myers SquibbEnrolling: 69020 locations
RECRUITINGPhase 1 / Phase 2NCT06128551

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C...

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated...

Sponsor: Revolution Medicines, Inc.Enrolling: 53420 locations
RECRUITINGNCT04155242

The Use of Biomarkers to Guide Management of Patients Treated With Radiofrequency Ablation for Early Oesophageal...

This prospective cohort study aims to assess the utility of a panel of molecular biomarkers for predicting the risk of relapse of Barrett's Oesophagus after endoscopic treatment...

Sponsor: University of CambridgeEnrolling: 1471 location
RECRUITINGPhase 2 / Phase 3NCT05427383

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together....

Sponsor: Shanghai JMT-Bio Inc.Enrolling: 2861 location
RECRUITINGPhase 3NCT03731442

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as...

Sponsor: Chinese Academy of Medical SciencesEnrolling: 3001 location
RECRUITINGNCT03835273

Oesophagectomy and Chest Wall and Respiratory Function

Open surgery for esophageal cancer commonly involves large incisions in the chest, associated with a high rate of pulmonary complications (30-50%). Minimally invasive approach...

Sponsor: Imperial College LondonEnrolling: 1001 location
RECRUITINGPhase 2NCT04939051

Obeticholic Acid for Prevention in Barrett's Esophagus

This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to...

Sponsor: National Cancer Institute (NCI)Enrolling: 308 locations
RECRUITINGPhase 1 / Phase 2NCT06780111

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 29820 locations
RECRUITINGPhase 3NCT04009265

Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma

A multi-center prospective randomized controlled study was conducted to compare the effects of adjuvant chemotherapy, chemoradiotherapy and surgery alone for the patients with...

Sponsor: Fujian Medical University Union HospitalEnrolling: 8191 location
RECRUITINGPhase 3NCT06840704

Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer

This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.

Sponsor: Hunan Cancer HospitalEnrolling: 1216 locations
RECRUITINGPhase 2NCT07437898

Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study

This is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma...

Sponsor: The Affiliated Hospital of Putian UniversityEnrolling: 421 location
RECRUITINGNCT06481449

Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Study

Cervical and upper thoracic esophageal cancer (ESCA) presents treatment challenges due to limited clinical evidence. This multi-center study (ChC\&UES) explores radical...

Sponsor: Hebei Medical University Fourth HospitalEnrolling: 26001 location
RECRUITINGPhase 1NCT07213791

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called...

Sponsor: Eli Lilly and CompanyEnrolling: 24120 locations
RECRUITINGNCT05892289

Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric...

Proximal early gastric cancer can choose radical total gastrectomy or proximal gastrectomy. The patients have poor nutritional status and quality of life after total gastrectomy....

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityEnrolling: 421 location
RECRUITINGNCT07050576

Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma

This study aims to develop a predictive model using deep learning and radiomics to assess the likelihood of lymph node metastasis in patients with early-stage esophageal squamous...

Sponsor: The First Affiliated Hospital of Anhui Medical UniversityEnrolling: 5001 location
RECRUITINGNCT06190847

Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal...

Esophageal cancer accounts for more than half of the world, seriously affecting people's health in China. 95% patients are squamous cell carcinoma. Surgery is the preferred...

Sponsor: Anhui Provincial HospitalEnrolling: 971 location
RECRUITINGNCT07165210

Incidence of 106TBL Lymph Node Metastasis

the study was to document the incidence of left tracheobronchial lymph node metastasis, and the risk factors of metastasis.

Sponsor: Fudan UniversityEnrolling: 18521 location
RECRUITINGNCT06387004

Radiation-Related Dysphagia Development Prediction Using a Two-Step Ultrasonographic Model (R-2D-2)

Radiotherapy for head and neck cancers (H\&NC) heightens the risk of swallowing disorders (SD), impacting nutrition, quality of life, and overall health, leading to increased...

Sponsor: Hopital ForcillesEnrolling: 1121 location
RECRUITINGPhase 1NCT06043466

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and...

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 302 locations
RECRUITINGNCT06137508

Cancer-associated Cachexia in Patients With Incurable Gastroesophageal Cancer

Patients with incurable gastroesophageal cancer are at high risk of cancer cachexia with an estimated prevalence of 60-80%. Cancer cachexia is defined as ongoing loss of skeletal...

Sponsor: Rigshospitalet, DenmarkEnrolling: 1251 location
RECRUITINGPhase 1NCT07085091

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid...

Sponsor: ALX Oncology Inc.Enrolling: 1707 locations
RECRUITINGPhase 3NCT04513808

Total Intravenous Anesthesia and Recurrence Free Survival

The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to...

Sponsor: The Cleveland ClinicEnrolling: 16141 location
RECRUITINGPhase 2NCT06354218

Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

This study is a Single Arm, Prospective, Exploratory, Single Center Phase II Clinical Study to evaluate the effectiveness of the combination of Serplulimab and Concurrent...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 501 location
RECRUITINGPhase 2NCT06718205

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

This study is a prospective, single-arm, multicenter study. The patients were given chemotherapy with nimotuzumab and sindilimab. To analyze the efficacy and safety of nimotuzumab...

Sponsor: The First Affiliated Hospital of Zhengzhou UniversityEnrolling: 1121 location
RECRUITINGPhase 1 / Phase 2NCT07488676

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid...

Sponsor: Astellas Pharma Global Development, Inc.Enrolling: 1508 locations
RECRUITINGPhase 2NCT05507411

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

To observe the 1-year disease-free survival rate (1-year PFS) of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined...

Sponsor: Zhejiang Cancer HospitalEnrolling: 1003 locations
RECRUITINGNCT03916809

EMST in Patients Undergoing CRT for HNCA

This study is a randomized trial examining the impact of expiratory muscle strength training (EMST) on maintenance of safe and efficient oropharyngeal swallow function in persons...

Sponsor: University of Wisconsin, MilwaukeeEnrolling: 302 locations
RECRUITINGPhase 2NCT06422403

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab,...

Sponsor: National University Hospital, SingaporeEnrolling: 3601 location
RECRUITINGPhase 3NCT06563869

Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

This study is a prospective, open-label, single-arm, single-center clinical study, aiming to evaluate the efficacy and safety of sintilimab combined with platinum-based...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 401 location
RECRUITINGNCT07482566

Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer

This multicenter prospective randomized clinical trial aims to compare the safety and oncological effectiveness of proximal gastrectomy and total gastrectomy in patients with...

Sponsor: Nurettin ŞahinEnrolling: 1201 location

Showing 50 of 106 trials.Search all Esophageal Cancer trials

Frequently Asked Questions

There are currently 106 clinical trials for Esophageal Cancer, with 106 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Esophageal Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Esophageal Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

For this entity, the underlying data on this page comes from the NIH ClinicalTrials.gov registry. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.